NasdaqGM - Delayed Quote USD

NKGen Biotech, Inc. (NKGN)

Compare
0.2300 -0.0161 (-6.54%)
At close: October 15 at 4:00 PM EDT
0.2388 +0.01 (+3.83%)
Pre-Market: 8:00 AM EDT
Loading Chart for NKGN
DELL
  • Previous Close 0.2461
  • Open 0.2606
  • Bid 0.1821 x 200
  • Ask 0.2633 x 200
  • Day's Range 0.2026 - 0.2606
  • 52 Week Range 0.2026 - 5.1000
  • Volume 731,983
  • Avg. Volume 946,570
  • Market Cap (intraday) 8.133M
  • Beta (5Y Monthly) 0.48
  • PE Ratio (TTM) --
  • EPS (TTM) -3.4200
  • Earnings Date Nov 12, 2024 - Nov 18, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

NKGen Biotech, Inc. operates as a clinical-stage biotechnology company that focuses on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies. Its lead products include SNK01, an autologous NK cell therapy candidate treatment for neurodegenerative diseases; and SNK02, an allogeneic NK cell therapy, which is in Phase 1 clinical trials for refractory solid tumors. The company has a license agreement with NKMAX. The company was formerly known as NKMAX America, Inc. NKGen Biotech, Inc. was founded in 2017 and is headquartered in Santa Ana, California. NKGen Biotech, Inc. operates as a subsidiary of NKMAX Co., Ltd.

nkgenbiotech.com

63

Full Time Employees

December 31

Fiscal Year Ends

Recent News: NKGN

View More

Performance Overview: NKGN

Trailing total returns as of 10/15/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

NKGN
91.64%
S&P 500
21.92%

1-Year Return

NKGN
92.33%
S&P 500
34.37%

3-Year Return

NKGN
96.29%
S&P 500
35.60%

5-Year Return

NKGN
96.29%
S&P 500
35.60%

Compare To: NKGN

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: NKGN

View More

Valuation Measures

Annual
As of 10/15/2024
  • Market Cap

    8.13M

  • Enterprise Value

    36.17M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    --

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -106.84%

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -88.25M

  • Diluted EPS (ttm)

    -3.4200

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    79k

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    12.75M

Research Analysis: NKGN

View More

Company Insights: NKGN

Research Reports: NKGN

View More

People Also Watch